FOR US EYE CARE PROFESSIONALS
IMPORTANT SAFETY INFORMATION FULL PRESCRIBING INFORMATION PATIENT INFORMATION MEDICAL INFORMATION PATIENT SITEThe ONLY nonsteroid anti-inflammatory Rx that can start to deliver dry eye symptom relief in just 2 WEEKS1*
*Xiidra significantly reduced symptoms of eye dryness at 2 weeks in 2 out of 4 clinical studies.1
Not an actual patient.
Not an actual patient.
The ONLY nonsteroid anti-inflammatory Rx that can start to deliver dry eye symptom relief in just 2 WEEKS1*
*Xiidra significantly reduced symptoms of eye dryness at 2 weeks in 2 out of 4 clinical studies.1
*Xiidra blocks LFA-1 on T cells from binding with ICAM-1 that may be overexpressed on the ocular surface in dry eye disease and may prevent formation of an immunologic synapse which, based on in vitro studies, may inhibit T-cell activation, migration of activated T cells to the ocular surface, and reduce cytokine release. The exact mechanism of action of Xiidra in dry eye disease is not known.1,2,5
Consider prescribing Xiidra, a first-in-class Rx therapy indicated for the treatment of the signs and symptoms of dry eye disease.1,2†
†Xiidra is an LFA-1 antagonist for the treatment of dry eye disease.1
Xiidra reduced symptoms of eye dryness (based on EDS) at 2 weeks in 2 out of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1
In 3 out of 4 studies, Xiidra showed notable improvements in signs (based on ICSS) of dry eye disease.1
The adverse reactions of Xiidra were studied across 5 clinical trials.§
Xiidra has ~90% overall coverage for Medicare Part D and commercial patients nationwide.3||
‡The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100). Effects on symptoms of dry eye disease: a larger reduction in EDS favoring Xiidra was observed in all studies at day 42 and day 84. Xiidra reduced symptoms of eye dryness at 2 weeks (based on EDS) compared to vehicle in 2 out of 4 clinical trials. Effects on signs of dry eye disease: at day 84, a larger reduction in ICSS favoring Xiidra was observed in 3 out of the 4 studies.1
§In 5 clinical studies of dry eye disease with lifitegrast ophthalmic solution, 1401 patients received at least 1 dose of lifitegrast (1287 of whom received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. One hundred-seventy patients were exposed to Xiidra for approximately 12 months. The most common adverse reactions (reported in 5-25% of patients) were instillation-site irritation, dysgeusia, and reduced visual acuity.1
||Based on data from October 2023. Up to 66% of Medicare Part D and 94% of commercial patients may be covered.3
IN THIS SECTION
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Important Safety Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Full Prescribing Information.
References
References
References
References
References
References
References
References
Reference
References
References
References
References
Reference
References
Reference
Reference
Reference
References
References
References
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
Important Safety Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Full Prescribing Information.